MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tauopathies"

  • 2016 International Congress

    Tau PET in Parkinson syndromes. A new diagnostic tool?

    J. Hammes, G.N. Bischof, K. Giehl, Ö. Onur, A. Drzezga, T. Klockgether, T. van Eimeren (Cologne, Germany)

    Objective: To explore the potential of [F-18]-AV-1451 PET as a diagnostic tool in Parkinson plus syndromes. Background: Clinically, atypical Parkinson syndromes are often difficult to…
  • 2016 International Congress

    [18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease

    J.B. Rowe, P. Vázquez Rodríguez, Y.T. Hong, R.J. Borchert, S. Sami, W.R. Bevan-Jones, S.P. Jones, R. Arnold, A. Surendranathan, E. Mak, S. Li, T. Fryer, J. O'Brien, L. Passamonti (Cambridge, United Kingdom)

    Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…
  • 2016 International Congress

    PET imaging of tau pathology in progressive supranuclear palsy

    S. Coakeley, S.S. Cho, P. Rusjan, A. Graff-Guerrero, R. Chen, A.E. Lang, L. Kalia, E. Slow, S. Houle, A.P. Strafella (Toronto, ON, Canada)

    Objective: This study aimed to determine whether there is an increase in [18F]-AV-1451 uptake in the brains of progressive supranuclear palsy (PSP) patients compared to…
  • 2016 International Congress

    Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome

    N. Upadhyay, A. Suppa, M.C. Piattella, F.D. Stasio, C. Colonnese, C. Colosimo, A. Berardelli, P. Pantano (Rome, Italy)

    Objective: To evaluate structural gray matter (GM) changes tested by surface-based measures of cortical thickness (CTh), surface area (SA) and volume (VOL), in order to…
  • 2016 International Congress

    In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET

    H. Endo, H. Shimada, Y. Kimura, M. Ichise, M. Ono, H. Shinotoh, F. Niwa, S. Kitamura, K. Takahata, S. Hirano, S. Koga, D.W. Dickson, N. Sahara, M. Yamada, M. Higuchi, T. Toda, T. Suhara (Chiba, Japan)

    Objective: This study was aimed at evaluating pathological tau accumulations in the brains of patients with progressive supranuclear palsy (PSP) and young and old healthy…
  • 2016 International Congress

    Tau dysfunction in the basal ganglia of a mouse model of tauopathy related to PSP

    A. Damianich, M. Sartor, S. Espindola, I.R.E. Taravini, O.S. Gershanik, J.E. Ferrario, M. Avale (Buenos Aires, Argentina)

    Objective: Determine motor coordination and neurochemical phenotypes in the basal ganglia of mice lacking the Tau protein or expressing an abnormal content of Tau isoforms.…
  • 2016 International Congress

    “Words untold”

    P.M. Iyer, B. McGuiness, J. Scott, S. Manning, A. Chalisseri, D. Olszewska, M. Farrell, T. Lynch (Dublin, Ireland)

    Objective: To highlight the salient clinical and pathologic features of primary progressive apraxia of speech through a clinical case presentation. Background: Apraxia of speech is…
  • 2016 International Congress

    Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum

    B. Bergmans, O. Deryck, R. Bruffaerts (Brugge, Belgium)

    Objective: Clinical characterization of a tauopathy spectrum patient. Background: In recent years phenotypic overlap has been demonstrated between patients with progressive supranuclear palsy (PSP) pathology…
  • 2016 International Congress

    FYN expression is associated with regulatory region genetic variation

    L.M. Bekris, J.A. Zahratka, Y. Shao, M. Shaw, K. Todd, M. Khrestian, J.B. Leverenz (Cleveland, OH, USA)

    Objective: The hypothesis of this investigation was that FYN expression and promoter activity are significantly influenced according to genetic content. The objective of this investigation…
  • 2016 International Congress

    Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome

    I. Aiba, Y. Saito, Y. Yokokawa, M. Kenjo, T. Katayama, R. Hashimoto, S. Sakakibara, A. Inukai, M. Mimuro, Y. Iwasaki, M. Yoshida (Nagoya, Japan)

    Objective: To elucidate specific clinical features of progressive supranuclear palsy (PSP) pathology in PSP syndrome. Background: PSP syndrome (PSPS) is the clinical hallmark of PSP;…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley